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Abstract
Background: Several states in the US have passed laws mandating coverage of colorectal cancer (CRC) screening
tests by health insurance plans. The impact of these state mandates on the use of colorectal cancer screening has
not been evaluated among an age-eligible target population with access to care (i.e., health care insurance
coverage).
Methods: We collected information on state mandates implemented by December 31, 2008 and used data on
insured adults aged 50 and 64 years from the Behavioral Risk Factor Surveillance System between 2002 and 2008
to classify individual-level exposure to state mandates for at least 1 year. Multivariate logistic regression models
(with state- and year- fixed effects, and patient demographic and socioeconomic characteristics) were used to
estimate the effect of state mandates on recent endoscopy screening (either flexible sigmoidoscopy or
colonoscopy during the past year).
Results: From 1999-2008, twenty-two states in the US, including the District of Columbia passed comprehensive
laws requiring health insurance coverage of CRC screening including endoscopy tests. Residence in states with CRC
screening coverage mandates in place for at least 1 year was associated with a 1.4 percentage point increase in
the probability of utilization of recent endoscopy (i.e., 17.5% screening rates in those with mandates versus 16.1%
in those without, Adjusted OR = 1.10, 95% CI: 1.02 - 1.20, p = 0.02).
Conclusions: The findings suggest a positive, albeit small, impact of state mandates on the use of recent CRC
screening endoscopy among the target eligible population with health insurance. However, more research is
needed to evaluate potential effects of mandates across health insurance types while including controls for other
system-level factors (e.g. endoscopy and primary care capacity). National health insurance reform should strive
towards a system that expands access to recommended CRC screening tests.
Background
Colorectal cancer (CRC) is the third leading cause of
cancer-related death in the U.S. among both men and
women [1]. CRC screening has been shown to reduce
colorectal cancer mortality as well as incidence, by vir-
tue of precancerous lesion detection and removal, and it
has been recommended for average risk adults aged 50
and older according to clinical guidelines [1-3]. The use
of CRC screening has been steadily rising; currently,
about half of US adults aged 50 years and older have
been screened for CRC with recommended testing mod-
alities (i.e. either a fecal occult blood test or endoscopy
tests) [4]. A number of factors are associated with lower
utilization of screening including racial or ethnic minor-
ity status, lower income and educational level and either
total lack of health insurance or inadequate health
insurance coverage, particularly with regard to endo-
scopy for CRC screening [5]. Other barriers to screening
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benefits, physician’s neglect to reinforce need for screen-
ing [5-8]. Based on a survey of health plans conducted
in 1999-2000, it was found that most health insurance
plans (97%) covered FOBT for average risk (asympto-
matic) patients. For the more invasive and expensive
CRC screening procedures, such as colonoscopy, a third
of the plans covered colonoscopy and nine percent cov-
ered flexible sigmoidoscopy but only for patients
deemed at high-risk. Also, this survey noted that for
eighty-five percent of covering plans, the patient
incurred cost-sharing, through co-insurance cost and/or
deductibles, for endoscopy testing procedures (average
range of charges $130 - $200 for flexible sigmoidoscopy
and $400 - $ 650 for colonoscopy) [9]. Patient cost-shar-
ing has been shown to reduce utilization of preventive
services and may influence preferences of CRC screen-
ing tests [10-12].
In recent years, in an effort to improve CRC screening
utilization promulgated by clinical guidelines as well as
to expand choice of tests given individual preferences,
[13-15] state policy makers have passed legislation in
several states to expand coverage for all recommended
tests for CRC screening. A few states, however, have
implemented policies specifying that either some CRC
t e s t sb ec o v e r e d( b u tn o ta l l )o rt h a tt h e yb eo f f e r e da s
part of the benefits and there remain a large number of
states that currently lack regulations [16]. The purpose
of this study was to assess the effect of state CRC
screening coverage mandates on self-reported utilization
of endoscopy (either flexible sigmoidoscopy or colono-
scopy testing) among an insured population of US
adults aged 50 to 64 years. Endoscopy testing was cho-
sen as the key outcome since it is expected that state
mandates requiring coverage of CRC screening would
primarily impact access to these expensive CRC screen-
ing modalities.
Methods
Data source
The Behavioral Risk Factor Surveillance System (BRFSS)
is a publicly available state level survey conducted in the
United States that measures information on general
health and cancer-related risk factors [17]. The BRFSS
conducts annual, state-based telephone surveys using a
multistage sampling design based on random-digit-
dialing methods to select a representative sample of the
non-institutionalized adult civilian population, more
details about the methodology can be found elsewhere
[18]. This study was exempted from IRB review since it
used publicly available BRFSS survey data consisting of
de-identified respondents records. In this study we used
four years of consecutive cross-sectional data from the
2002, 2004, 2006 and 2008 survey years of the BRFSS
that collected information on two endoscopy screening
modalities (flexible sigmoidoscopy or colonoscopy) [18].
Information about CRC screening mandates was derived
from the Health Policy Tracking service of the Ameri-
can Cancer Society Cancer Action Network [16].
Analytic sample
From the compiled four-year cross-sectional BRFSS survey
data, we derived an analytic sample consisting of respon-
dents aged 50 to 64 years who indicated having any health
insurance coverage and were residing in 44 states or D.C.
(details of state exclusions are explained below).
Variables
CRC legislation
For the purpose of these analyses, states with coverage
mandates for CRC screening were those that had imple-
mented comprehensive legislation requiring private
insurance plans to cover the full range of colorectal can-
cer screening tests, including endoscopy procedures,
consistent with American Cancer Society guidelines [1]
on or before December 31, 2008 [16]. States were
excluded if they mandated partial coverage of some tests
(Wyoming), “Offers” of coverage (Alabama, Oklahoma
and Tennessee), or had voluntary agreements with
insurance companies to provide coverage (New York
and Vermont) (Table 1). For each respondent, we cre-
ated a measure of CRC screening legislation ‘age’ (i.e.,
time since date of laws’ implementation) by calculating
the difference in years between the date of passage of
the law and the date of interview. A respondent was
considered as exposed if they had resided in a state with
the law for 1 year or more prior to the date of their
interview. Respondents who at the time of interview had
mandates for less than 1 year or those in states with no
mandates were considered as not exposed. As such
respondents in a state in a particular year may have a
different exposed/non-exposed status.
CRC screening outcome
In the BRFSS, participants were read this script (“Sigmoi-
d o s c o p ya n dc o l o n o s c o p ya r ee x a m si nw h i c hat u b ei s
inserted in the rectum to view the colon for signs of can-
cer or other health problems”) to enable recall and
reporting of endoscopy screening for CRC. Then, partici-
pants’ information on endoscopy testing was collected by
asking these two questions: “Have you ever had either of
these exams?” and “How long has it been since you had
your last sigmoidoscopy or colonoscopy?” From this
information, we defined the outcome as a dichotomous
(yes/no) measure of the receipt of an endoscopy CRC
screening test in the past year. Though clinical guidelines
recommend varying intervals for different types of endo-
scopy testing for CRC, we used the ‘past year’ interval in
order to minimize potential misclassification of case/
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tion between states with and without laws.
Covariates
All multivariate analyses controlled for age (categorized
as 50 to 54 years old, 55 to 59 years old and 60 to
64 years old), sex (male vs female), race/ethnicity (non-
Hispanic White, non-Hispanic Black, Hispanic, and
others races), education level (having less than or equal
to a high school degree versus having some college or
college graduate education), household income level
(annual income of less than $25,000, between $25,000 to
less than $50,000, over $50,000 and a category of ‘miss-
ing’ was included also since more than five percent of
t h es a m p l eh a d‘unknown’ income information), self-
reported health status (categories of fair or poor health,
good and better health), and marital status (married,
single and divorced/widowed or separated individuals).
Even though state mandates primarily affect privately
insured populations, the BRFSS did not collect informa-
tion about the type of health plans among those with
health insurance coverage. As we could not restrict our
analytic sample to the privately insured group, we con-
sidered a state level variable measuring the privately
insured proportion among 50-64-year-olds (divided into
tertiles and classified as high, medium, and low) for
2002, 2004, 2006 and 2008 as a covariate in all statistical
models [19] in addition to controlling for respondents’
socioeconomic status.
Statistical analysis
The independent effect of state CRC screening coverage
mandates on CRC screening was evaluated using state-
and year- fixed effects models. Multivariate logistic
regression analyses were used to calculate adjusted
probabilities (predicted marginals) and odds ratios of
colorectal cancer screening among respondents with
and without state coverage mandates. Models included a
state fixed effect that controlled for state factors that do
no vary over time (invariant factors) and a year effect
that controlled for national secular trends, in addition to
individual-level covariates, and state privately insured
population rates among those 50-64 years. We present
these estimates in comparison with unadjusted probabil-
ities (obtained from unadjusted logistic regression mod-
els) in order to understand the influence of other
covariates on the relationship between state mandates’
exposure and screening probabilities. Further, we per-
formed sensitivity analysis that considered a lag variable
in order to capture the effect of mandates at different
times after implementation. We tested for significant
differences in the adjusted rates among residents in
states with mandates for different time periods after
implementation (1 year, 2 to 4 years, 5 years or more).
We tested for potential two- and three-way interac-
tions between the mandates and demographic (race and
ethnicity) and SES variables (education- and income-
level), as it is plausible that the effect of these mandates
would be more concentrated among certain groups than
others, given that some groups may have had lower
access to these tests prior to the passage of these man-
dates and may thus benefit more after these laws are
passed. SAS-callable-SUDAAN Version 10 was used to
apply the sampling weights in the calculation of
weighted estimates and standard errors (using Taylor
Series Linearization Method [20]) that take into account
the complex survey design of the BRFSS surveys [18].
Results
State mandates and Sample characteristics
Of the 45 states included in the study, 22 states and DC
had passed mandates requiring private insurance plans
to cover the full range of colorectal cancer screening
tests consistent with ACS guidelines on or before
D e c e m b e r3 1 ,2 0 0 8( T a b l e1 ) .T h ea n a l y t i cs a m p l ec o n -
sisted of 293,626 individuals aged 50-64 years who
reported having health insurance coverage (Table 2).
Respondents were evenly distributed across years (2002
to 2008) and between the sexes (49% male vs. 51%
female). Individuals were mostly in the age-groups of
Table 1 States with Colorectal Cancer Screening
Coverage Mandates
State Date of implementation
Missouri 28-Aug-99
West Virginia 1-Apr-00
Indiana 1-Jul-00
Virginia 1-Jul-00
California 27-Sep-00
Rhode Island 31-Dec-00
Delaware 1-Jan-01
Maryland 1-Jul-01
Texas 1-Sep-01
Connecticut 1-Oct-01
North Carolina 1-Jan-02
Distict of Columbia 13-Apr-02
New Jersey 1-Jul-02
Georgia 1-Jul-02
Nevada 10-Oct-03
Illinois 1-Jan-04
Arkansas 1-Aug-05
Oregon 23-Aug-05
Louisiana 1-Jan-06
Alaska 1-Jan-07
New Mexico 1-Apr-07
Washington 1-Jul-08
Note: States were excluded if they mandated partial coverage of some tests,
“Offers” of coverage, or had voluntary agreements with insurance companies
to provide coverage.
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White, non-Hispanic (79.1%), had college or some col-
lege degrees (65.8%), and in higher- and middle-house-
hold income groups (≥$50,000: 50.8%, 25,000 to
≤50,000: 23.6%). The majority of respondents reported
“better” or “good” health status (81.9%), and were
married or members of unmarried couples (74.7%)
(Table 2). Across states, the percent of the population
50-64 years who were privately insured averaged over
2002-2008 was generally high and ranged from 69% in
Arkansas to 88% in Minnesota (data not shown).
Impact of state CRC screening mandates on CRC
screening utilization in the past year
In unadjusted analyses, having a state CRC screening
mandate for at least 1 year was associated with a 0.4%
point increase in the probability of flexible sigmoido-
scopy or colonoscopy in the past year (OR: 1.03, 95%
CI: 0.99, 1.08, p = 0.09) (Table 3). Adjustment for state-
and year-fixed effects, individual covariates, and state-
level proportions of privately insured adults resulted in
a stronger mandate effect compared to unadjusted ana-
lyses; the probability of CRC screening was 1.4% points
higher among individuals residing in states with man-
dates than those without (17.5% vs. 16.1%, OR: 1.10,
95% CI: 1.02, 1.20, p = 0.02) (Table 3). Additionally, we
considered the possibility that state mandates require
more than one year of implementation to be effective in
changing CRC utilization patterns. CRC utilization rates
did not differ significantly between respondents in states
with laws in place for different time intervals.
The two-way interaction terms between state mandates
and demographic- and socioeconomic- variables were
not statistically significant; indicating that the effect of
mandates did not differ significantly between subgroups
of respondents based on their race/ethnicity, education,
and household income levels (data not shown). However,
linear contrasts of the adjusted probabilities indicated
that the effect of mandates was significant and stronger
in higher-educated respondents (16.7% vs. 18.3%, con-
trast: 1.6% points, p = 0.01) but not in lower-educated
respondents (15% vs. 15.8%, contrast: 0.8%, p = 0.12).
A three-way interaction variable between state mandates,
a collapsed two-level version of the household income
(low- and middle-income: < $50,000, and high income
group: ≥$50,000), and education level (lower-education:
less than high school or high school graduate, and
higher-education: college graduate or some college grad-
uate) was statistically significant (p < 0.005). Linear con-
trasts of the adjusted probabilities from the interaction
term indicated that among low- and middle-income indi-
viduals, the effect of state mandates was positive and sig-
nificant only among higher-educated individuals (14.4%
vs. 17.9%, contrast: 3.5% points, p < 0.001) but not
among lower-educated individuals (13.7% vs. 14.1%, con-
trast: 0.4% points, p = 0.5). Conversely, state mandates
resulted in marginally higher CRC utilization rates
among lower educated-high income individuals (15.3%
vs. 18.0%, contrast: 2.7% points, p < 0.05), but not among
high educated-high income individuals (17.9% vs. 19.1%,
contrast: 1.2% points, p = 0.12).
Table 2 Descriptive characteristics of US Adults with
Health Insurance, aged 50-64 years, surveyed in the
period of 2002-2008
Characteristics Unweighted,
N (%)
Weighted %
Year of the survey
2002 45465 (15.5) 22.3
2004 62271 (21.2) 23.7
2006 82923 (28.2) 26.1
2008 102967 (35.1) 27.9
Age
50-54 105041 (35.8) 40.6
55-59 100781 (34.3) 32.8
60-64 87804 (29.9) 26.6
Sex
Male 117328 (40.0) 49.0
Female 176298 (60.0) 51.0
Annual Household income
<25,000 50398 (17.2) 14.8
25,000-<50,000 75277 (25.6) 23.6
> = 50000 135243 (46.1) 50.8
Missing 32568 (11.1) 10.8
Education
Less than high school or High School 100382 (34.2) 34.2
Some college or College graduate 192786 (65.8) 65.8
Race
White, non-Hispanic 246930 (84.4) 79.1
Black, non-Hispanic 19904 (6.8) 8.0
Hispanic 10685 (3.7) 7.4
Other, Multi-racial, non-Hispanic 13615 (4.7) 5.5
Health status
Excellent or Very good 678834 (51.5) 53.6
Good 396194 (30.1) 30.1
Fair or poor 241939 (18.4) 16.3
Marital status
Divorced/Widowed/Separated 81354 (27.8) 20.0
Single 21170 (7.2) 5.2
Married/member of unmarried couple 190143 (65.0) 74.7
State privately insured population*
Low 79047 (26.9) 38.7
Medium 101351 (34.5) 30.2
High 113228 (38.6) 31.1
Note: Missing responses constituted less than 0.8% on all of the above
variables, except income for which missing values were coded as a separate
category. * State-level variable from the Census[19] and expressed in tertiles
of the distribution of the states’ proportion of adults aged 50 to 64 years with
private insurance.
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In this study, we provide the first assessment of the uti-
lization effects of state mandates requiring private
insurers to cover recommended CRC screening. The
main findings suggest that state mandates are positively
associated with utilization of CRC endoscopic screening
(1.4% absolute increase in probability of past-year endo-
scopy test use) in adults aged 50 to 64 years with access
to care. In addition, our results suggest that among low-
and middle- income groups, mandates seemed to have
Table 3 Impact of Colorectal Cancer Screening coverage mandates on Endoscopy Screening
a Use in Past Year among
US Adults with Health Insurance aged 50-64 years, 2002-2008
Characteristic Unadjusted prevalence
(95% CI)
OR (95% CI) Adjusted prevalence
b
(95% CI)
OR (95% CI)
CRC Screening Mandate
State mandate for at least 1 year 16.9 (±0.4) 1.03 (0.99, 1.08) 17.5 (±0.7) 1.10 (1.02, 1.20)*
State mandate for less than 1 year or No state
mandate
16.5 (±0.4) 1.00 16.1 (±0.5) 1.00
Covariates
Year of the survey
2008 17.9 (±0.4) 1.23 (1.16, 1.3)*** 17.5 (±0.5) 1.16 (1.09, 1.24)***
2006 17.4 (±0.6) 1.18 (1.12, 1.25) 17.2 (±0.5) 1.13 (1.06, 1.21)
2004 16.0 (±0.6) 1.07 (1.01, 1.14) 16.1 (±0.6) 1.05 (0.98, 1.12)
2002 15.1 (±0.6) 1.00 15.5 (±0.6) 1.00
Age
50-54 15.2 (±0.4) 0.77 (0.73, 0.81)*** 15.1 (±0.4) 0.76 (0.72, 0.79)***
55-59 16.8 (±0.4) 0.87 (0.83, 0.91) 16.7 (±0.5) 0.86 (0.81, 0.90)
60-64 18.9 (±0.6) 1.00 19.0 (±0.5) 1.00
Sex
Male 16.9 (±0.4) 1.04 (1.00, 1.08)* 16.8 (±0.4) 1.01 (0.97, 1.05)
Female 16.4 (±0.4) 1.00 16.6 (±0.3) 1.00
Annual Household Income
<25,000 15.5 (±0.6) 0.86 (0.81, 0.91)*** 14.7 (±0.7) 0.80 (0.75, 0.86)***
25,000-<50,000 15.4 (±0.6) 0.85 (0.81, 0.89) 15.5 (±0.5) 0.85 (0.81, 0.89)
> = 50000 17.5 (±0.4) 1.00 17.7 (±0.4) 1.00
Missing 17.2 (±0.8) 0.98 (0.92, 1.04) 17.1 (±0.8) 0.96 (0.89, 1.02)
Education
Less than high school or High School 15.4 (±0.4) 0.87 (0.83, 0.90)*** 15.3 (±0.5) 0.86 (0.82, 0.90)***
Some college or College graduate 17.4 (±0.4) 1.00 17.4 (±0.4) 1.00
Race
Black, non-Hispanic 20.7 (±1.2) 1.33 (1.24, 1.43)*** 21.1 (±1.2) 1.38 (1.28, 1.48)***
Hispanic 15.3 (±1.4) 0.92 (0.82, 1.03) 16.3 (±1.5) 1.01 (0.90, 1.13)
Other, Multi-racial, non-Hispanic 16.5 (±1.6) 1.00 (0.89, 1.14) 16.9 (±1.7) 1.05 (0.93, 1.19)
White, non-Hispanic 16.4 (±0.2) 1.00 16.3 (±0.3) 1.00
Health status
Fair or poor health 19.2 (±0.8) 1.24 (1.18, 1.3)*** 20.4 (±0.8) 1.36 (1.29, 1.44)***
Good or better health 16.1 (±0.2) 1.00 15.9 (±0.3) 1.00
Marital status
Divorced/Widowed/Separated 15.9 (±0.6) 0.92 (0.88, 0.96)*** 15.9 (±0.5) 0.92 (0.88, 0.97)***
Single 15.2 (±1.2) 0.87 (0.8, 0.95) 15.2 (±1.1) 0.87 (0.80, 0.96)
Married/member of unmarried couple 17.0 (±0.4) 1.00 17.0 (±0.3) 1.00
State privately insured population
Low 16.4 (±0.5) 0.92 (0.88, 0.96)*** 16.9 (±1.1) 1.02 (0.89, 1.17)
Medium 16.2 (±0.4) 0.91 (0.87, 0.94) 16.6 (±0.7) 1.00 (0.93, 1.07)
High 17.6 (±0.4) 1.00 16.6 (±0.9) 1.00
* p < 0.05, ** P < 0.01, ***p < 0.001; 95% CI: 95% confidence interval; OR: Odds ratio; CRC: Colorectal Cancer.
a Endoscopy screening is defined as having ever had either sigmoidoscopy and colonoscopy and reporting receipt of any of these screening tests in the past
year.
b Adjusted prevalences are predicted marginals derived from multivariate logistic models predicting endoscopy use, that adjusted for covariates listed
above, in addition to state fixed effects.
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educated, whereas education-related disparities in high
income groups appear to have been reduced as a result
of mandates. Even though we know of no prior study
that has examined this association in a non-Medicare
insured population of adults aged 50 to 64 years, our
study findings are generally consistent with previous stu-
dies conducted among the elderly Medicare benefici-
aries, showing positive effects of policy changes [21-24].
In reflecting on these study’s finding suggesting a
small effect of state CRC screening mandates (in abso-
lute percentage differences), we have to consider several
contextual issues and challenges that may stimulate
additional health policy research endeavors. First, there
i st h ei s s u et h a ts t a t e - m a n d a t e db e n e f i t sf o rC R C
screening are limited in their reach because of certain
exemptions. State mandates only apply to certain types
of insurance coverage in the commercial private market-
place. It is the case that, the federal Employee Retire-
ment Income Security Act (ERISA) exempts states from
regulating self-funded employer-based health plans from
state laws that govern health insurance [25,26]. We were
unable to distinguish and exclude individuals subject to
these self-insured plans, potentially biasing our estimates
towards the null. Secondly, we had very limited informa-
tion on respondents’ health insurance plans. We were
unable to restrict our sample to privately insured
respondents, although we considered the inclusion of a
state measure of privately insured populations as an
adjustment factor. Further, we could not account for
potential differences across types of private insurance (e.
g. managed-care plans, fee-for-service, high-deductible
health service accounts, etc); such variations in types of
private insurance arrangements may play a role in utili-
zation of medical services [27]. Thirdly, although man-
dated benefits for CRC screening may have expanded
options for CRC testing modalities they do not address
the cost-sharing requirements for the more expensive
modalities (i.e., sigmoidoscopy and colonoscopy). Studies
have shown that patient-cost sharing requirements influ-
ence preferences for specific CRC screening tests and
are likely to reduce utilization of preventive services
[10-12]. Another issue is that despite state-mandated
benefits resulting in changes to health plan policies for
CRC screening, certain socioeconomic segments may
still access these expanded benefits at disproportionately
lower/higher rates vis-à-vis other groups. Our results
suggest CRC endoscopy uptake patterns after passage of
state mandates may be a function both individuals’ edu-
cation and income levels which may in turn relate to
other influences such as patients’ knowledge of
expanded benefits and eligibility requirements and
receipt of healthcare provider CRC screening recom-
mendation [28-30]. Despite state mandates, patients’
ability to obtain an endoscopy test (or a referral) may be
affected by the availability of endoscopy-infrastructure
services/providers. Thus, future studies are needed to
better characterize whether and how these issues/con-
cerns affect the robustness/validity of our findings.
Lastly, our study was limited by its reliance on self-
reported survey data and so future studies based on
claims and/or clinic records are needed.
Conclusion
Screening for colorectal cancer is a beneficial, cost-
effective way to advance the public’sh e a l t hb y
reducing the incidence and mortality of CRC [1,5].
Colorectal cancer screening has been designated as
o n eo ft h eh i g h e s tp r i o r i t yp r e v e n t i v es e r v i c e sb yt h e
National Commission on Preventive Priorities based on
the burden of disease that could be prevented [31,32].
It is increasingly recognized that all age-eligible asymp-
tomatic adults have adequate and affordable access to
all recommended screening procedures in order to
improve survival and quality of life [27]. Our study
suggests that state mandates for CRC screening test
coverage may increase utilization among insured indi-
viduals. Through advocacy efforts, colorectal cancer
screening and prevention has been part of the national
healthcare reform discussions and much is expected
with the recent passage of landmark federal legislation,
the Patient Protection and Affordable Care Act [33].
This Act requires all new private health plans cover
colorectal cancer screening tests with a U.S. Preventive
Services Task Force (USPSTF) rating of “A” or “B”
without any out-of-pocket costs to patients [34]. Now,
with the advent of its implementation, there is yet the
potential for future improvements in CRC screening
test utilization as it intends to prioritize access to pre-
v e n t i v ec a r ef o ra l l ,i n c l u d i n gp r e v i o u s l yu n i n s u r e d
individuals.
Acknowledgements
We thank Dana Flanders, PhD. for his valuable statistical consultation on the
methods and statistical analysis of the study.
Author details
1Surveillance and Health Policy Research, American Cancer Society, Atlanta,
USA.
2Cancer Action Network - American Cancer Society, Washington DC, USA.
Authors’ contributions
VC initiated the research idea, designed the study, and wrote the
manuscript. PB contributed to the study design, conducted the analysis and
wrote parts of the manuscript. MS provided valuable support in the
compilation of state mandates information as well as review/editing of the
manuscript. KV provided valuable comments on the analysis and editorial
suggestions on the manuscript. EW provided valuable comments and
editorial suggestion on the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Cokkinides et al. BMC Health Services Research 2011, 11:19
http://www.biomedcentral.com/1472-6963/11/19
Page 6 of 7Received: 6 August 2010 Accepted: 27 January 2011
Published: 27 January 2011
References
1. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS,
Dash C, Giardiello FM, Glick S, Levin TR, et al: Screening and Surveillance
for the Early Detection of Colorectal Cancer and Adenomatous Polyps,
2008: A Joint Guideline from the American Cancer Society, the US Multi-
Society Task Force on Colorectal Cancer, and the American College of
Radiology. CA Cancer J Clin 2008, 58(3):130-160.
2. US Preventive Services Task Force: Screening for colorectal cancer:
recommendations and rationale. Agency for Healthcare Research and
Quality, Rockville, MD; 2002.
3. Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P,
Lave JR, Laveist TA, Ness RB, et al: NIH State-of-the-Science Conference
Statement: Enhancing Use and Quality of Colorectal Cancer Screening.
NIH 2010, 27(1).
4. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW: Cancer screening
in the United States, 2010: a review of current American Cancer Society
guidelines and issues in cancer screening. CA Cancer J Clin 2010,
60(2):99-119.
5. Holden DJ, Jonas DE, Porterfield DS, Reuland D, Harris R: Systematic
review: enhancing the use and quality of colorectal cancer screening.
Ann Intern Med 2010, 152(10):668-676.
6. Zapka JG, Puleo E, Vickers-Lahti M, Luckmann R: Health systems factors
and colorectal cancer screening. Am J Prev Med 2002, 23(1):28-35.
7. Adams EK, Thorpe KE, Becker ER, Joski PJ, JF: Colorectal cancer screening,
1997-1999: role of income, insurance and policy. Prev Med 2005,
38(5):551-557.
8. Farmer MM, Bastani R, Kwan L, Belman M, Ganz PA: Predictors of
colorectal cancer screening from patients enrolled in a managed care
health plan. Cancer 2008, 112(6):1230-1238.
9. Klabunde CN, Riley GF, Mandelson MT, Frame PS, Brown ML: Health plan
policies and programs for colorectal cancer screening: a national profile.
Am J Manag Care 2004, 10(4):273-279.
10. Pignone M, Bucholtz D, Harris R: Patient preferences for colon cancer
screening. J Gen Intern Med 1999, 14:432-437.
11. Varghese RK, Friedman C, Ahmed F, Franks AL, Manning M, Seeff LC: Does
Health Insurance Coverage of Office Visits Influence Colorectal Cancer
Testing. Cancer Epidemiol Biomarkers Prev 2005, 14(3):744-747.
12. Wharam JF, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D,
Landon BE: Cancer Screening before and after Switching to a High-
Deductible Health Plan. Ann Intern Med 2008, 148:647-655.
13. Powell AA, Burgess DJ, Vernon SW, Griffin JM, Grill JP, Noorbaloochi S,
Partin MR: Colorectal cancer screening mode preferences among US
veterans. Prev Med 2009, 49(5):442-448.
14. Jones RM, Woolf SH, Cunningham TD, Johnson RE, Krist AH, Rothemich SF,
Vernon SW: The Relative Importance of Patient-Reported Barriers to
Colorectal Cancer Screening. 38 2010, 5:499-507.
15. Fletcher RH, Colditz GA, Pawlson LG, Richman H, Rosenthal D, Salber PR:
Screening for colorectal cancer: the business case. Am J Manag Care
2002, 8:531-538.
16. Issue Brief: How do you measure up? A Progress Report on State
Legislative Activity to reduce cancer incidence and mortality. 2010
[http://acscan.org/static/measure/].
17. Centers for Disease Control and Prevention (CDC): Behavioral Risk Factor
Surveillance System operational and user’s guide. Atlanta, GA: US
Department of Health and Human Services, CDC; 2006 [http://www.cdc.
gov/BRFSS/], Accessed Jun 15, 2010.
18. Centers for Disease Control and Prevention (CDC): Behavioral Risk Factor
Surveillance Systems - Technical Documentation. 2010 [http://www.cdc.
gov/brfss/technical_infodata/surveydata.htm].
19. Census: American Community Survey 2002-2008. U.S Census Bureau:
DataFerrett; 2010.
20. SUDAAN: version 9.0.0 Software for the Statistical Analysis of Correlated
Data. Research Triangle Institute, Inc NC; 2002.
21. Meissner HI, Breen N, Klabunde CN, Vernon SW: Patterns of colorectal
cancer screening uptake among men and women in the United States.
Cancer Epidemiol Biomarkers Prev 2006, 15(2):389-394.
22. Schenck AP, Peacock SC, Klabunde CN, Lapin P, Coan JF, Brown ML: Trends
in colorectal cancer test use in the Medicare population, 1998-2005. Am
J Prev Med 2009, 37:1-7.
23. Harewood GC, Lieberman DA: Colonoscopy practice patterns since
introduction of Medicare coverage for average-risk screening. Clin
Gastroenterol Hepatol 2004, 2(1):72-77.
24. Prajapati DN, Saeian K, Binion DG, Staff DM, Kim JP, Massey BT, Hogan WJ:
Volume and yield of screening colonoscopy at a tertiary medical center
after change in medicare reimbursement. Am J Gastroenterol 2003,
98(1):194-199.
25. Issue Brief. State strategies for curbing colorectal cancer screening. NGA
Center for Best Practices, Washington DC; 2008.
26. Buchmueller TC, Cooper PF, Jacobson M, Zuvekas SH: Parity for Whom?
Exemption and the extent of state mental health parity legislation.
Health Affairs 2007, 26(4):w483-487.
27. Barrera E, Ward E, Shah M: Impact of Health insurance on colorectal
cancer screening. In Early Detection and Prevention of Colorectal Cancer.
Edited by: Kim KE. SLACK Incorporated, Thorofare, NJ; 2009.
28. Ruffin MT, Creswell JW, Jimbo M, Fetters MD: Factors influencing choices
for colorectal cancer screening among previously unscreened African
and Caucasian Americans: findings from a triangulation mixed methods
investigation. J Community Health 2009, 34(2):79-89.
29. Hawley ST, Volk RJ, Krishnamurthy P, Jibaja-Weiss M, Vernon SW, S K:
Preferences for colorectal cancer screening among racially/ethnically
diverse primary care patients. Med Care 2008, 46(9 Suppl 1):S10-16.
30. Ye J, Xu Z, Aladesanmi O: Provider recommendation for colorectal cancer
screening: examining the role of patients’ socioeconomic status and
health insurance. Cancer Epidemiol Biomarkers Prev 2009, 33:207-211.
31. Maciosek MV, Edwards NM, Coffield AB, Flottemesch TJ, Nelson WW,
Goodman MJ, Solberg LI: Priorities among effective clinical preventive
services: methods. Am J Prev Med 2006, 31(1):90-96.
32. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ:
Colorectal cancer screening: health impact and cost effectiveness. Am J
Prev Med 2006, 31(1):80-89.
33. The Patient Protection and Affordable Care Act. Pub L. No. 111-148.
2011 [http://www.healthcare.gov/law/about/index.html ].
34. Interim Final Rules for Group Health Plans and Health Insurance Issuers
relating to coverage of preventive services under the Patient Protection
and Affordable Care Act, July 19 2010. 2011 [http://www.healthcare.gov/
law/provisions/preventive/moreinfo.html].
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/11/19/prepub
doi:10.1186/1472-6963-11-19
Cite this article as: Cokkinides et al.: The association between state
mandates of colorectal cancer screening coverage and colorectal
cancer screening utilization among US adults aged 50 to 64 years with
health insurance. BMC Health Services Research 2011 11:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cokkinides et al. BMC Health Services Research 2011, 11:19
http://www.biomedcentral.com/1472-6963/11/19
Page 7 of 7